[{"id":"32db2e33-a236-469e-bb51-b652b3d549e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05136846","created_at":"2021-11-29T14:53:44.432Z","updated_at":"2025-02-25T17:01:33.441Z","phase":"Phase 1","brief_title":"Papaverine in Combination with Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05136846","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • Pemfexy (pemetrexed) • papaverine"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 12/06/2021","start_date":" 12/06/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-03"}]